Trpm4 channel inhibitors for stroke treatment

Abstract

The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (TRPM4) channel. The present invention also provides uses of TRPM4 inhibitors, TRPM4 antibodies and kits for use in the methods of the invention.

1 .- 7 . (canceled) 
     
     
         8 . A method of treating ischemic stroke, comprising administering to a subject in need thereof an efficacious amount of at least one TRPM4 inhibitor. 
     
     
         9 . The method according to  claim 8 , wherein the at least one inhibitor is an antibody or a fragment thereof which specifically binds to TRPM4, or is a TRPM4-specific siRNA. 
     
     
         10 . The method according to  claim 9 , wherein the antibody is a polyclonal antibody, a mouse monoclonal antibody, or a humanized monoclonal antibody, or a fragment thereof. 
     
     
         11 . The method according to  claim 9 , wherein the siRNA comprises a sense oligonucleotide comprising SEQ ID NO: 7 and an antisense oligonucleotide comprising SEQ ID NO: 8. 
     
     
         12 . The method according to  claim 8 , wherein the at least one TRPM4 inhibitor is administered in combination with one or more thrombolytic agents. 
     
     
         13 . The method according to  claim 8 , wherein the at least one TRPM4 inhibitor is administered during the acute stage and/or the chronic stage. 
     
     
         14 . The method according to  claim 8 , wherein treatment increases angiogenesis in the subject. 
     
     
         15 . The method according to  claim 8 , wherein treatment reduces infarct volume in the subject. 
     
     
         16 . The method according to  claim 8 , wherein treatment extends the therapeutic time window for reperfusion. 
     
     
         17 .- 25 . (canceled)